Severe cutaneous adverse drug reactions: Who should treat, Where and how?: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 3, 2010, Pages 344-348

  Wolf, Ronni ^a   Davidovici, Batya ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DRUG; IMMUNOGLOBULIN; PREDNISONE; STEROID;

ARTICLE; BURN; CLINICAL FEATURE; DRUG ERUPTION; HUMAN; PATIENT TRANSPORT; PRIORITY JOURNAL; RESPONSIBILITY; SEVERE CUTANEOUS ADVERSE REACTION; SKIN EXFOLIATION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYMPTOM; TEAMWORK; TOXIC EPIDERMAL NECROLYSIS; BURN UNIT; DERMATOLOGY; ORGANIZATION AND MANAGEMENT; PATIENT CARE PLANNING; PRACTICE GUIDELINE; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME;

ADRENAL CORTEX HORMONES; BURN UNITS; DERMATOLOGY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PATIENT CARE PLANNING; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME;

EID: 77953592420     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.06.020     Document Type: Article

References (35)

1. Wolkenstein P., Latarjet J., Roujeau J.C., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998, 352:1586-1589.
2. Chave T.A., Mortimer N.J., Sladden M.J., Hall A.P., Hutchinson P.E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005, 153:241-253.
3. Pereira F.A., Mudgil A.V., Rosmarin D.M. Toxic epidermal necrolysis. J Am Acad Dermatol 2007, 56:181-200.
4. Criton S., Devi K., Sridevi P.K., Asokan P.U. Toxic epidermal necrolysis-a retrospective study. Int J Dermatol 1997, 36:923-925.
5. Zoltie N., Verlende P., O'Neill T.J., McKenzie A.W. Lyell's syndrome on a burns unit. Burns 1994, 20:368-370.
6. Hettiaratchy S., Moloney D., Clarke J. Patients with acute skin loss: are they best managed on a burns unit?. Ann R Coll Surg Engl 2001, 83:26-29.
7. Smoot E.C. 3rd. Treatment issues in the care of patients with toxic epidermal necrolysis. Burns 1999, 25:439-442.
8. Palmieri T.L., Greenhalgh D.G., Saffle J.R., et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002, 23:87-96.
9. Bastuji-Garin S., Rzany B., Stern R.S., Shear N.H., Naldi L., Roujeau J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993, 129:92-96.
10. Imahara S.D., Holmes J.H., Heimbach D.M., et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006, 27:270-275.
11. Wolf R., Ruocco V., Jablonska S. Treatment of toxic epidermal necrolysis syndrome with "disease-modifying" drugs: the controversy goes on. Clin Dermatol 2004, 22:267-269.
12. Anhalt G., Snelling C.F. Toxic epidermal necrolysis. Case report. Plast Reconstr Surg 1978, 61:905-910.
13. Bjornberg A. Fifteen cases of toxic epidermal necrolysis (Lyell). Acta Derm Venereol 1973, 53:149-152.
14. Ohlenschlaeger K. Toxic epidermal necrolysis and Stevens-Johnson's disease. Acta Derm Venereol 1966, 46:204-209.
15. Sherertz E.F., Jegasothy B.V., Lazarus G.S. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy. J Am Acad Dermatol 1985, 12:178-181.
16. Patterson R., Grammer L.C., Greenberger P.A., et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc 1992, 13:89-95.
17. Cheriyan S., Patterson R., Greenberger P.A., Grammer L.C., Latall J. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995, 16:151-155.
18. Stables G.I., Lever R.S. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993, 128:357.
19. Rasmussen J.E. Erythema multiforme in children. Response to treatment with systemic corticosteroids. Br J Dermatol 1976, 95:181-186.
20. Rasmussen J.E. Toxic epidermal necrolysis. A review of 75 cases in children. Arch Dermatol 1975, 111:1135-1139.
21. Halebian P., Corder V., Madden M., et al. A burn center experience with toxic epidermal necrolysis. J Burn Care Rehabil 1983, 4:176-183.
22. Halebian P.H., Corder V.J., Madden M.R., Finklestein J.L., Shires G.T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986, 204:503-512.
23. Halebian P.H., Shires G.T. Burn unit treatment of acute, severe exfoliating disorders. Annu Rev Med 1989, 40:137-147.
24. Jones W.G., Halebian P., Madden M., Finkelstein J., Goodwin C.W. Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg 1989, 24:167-170.
25. Kelemen J.J., Cioffi W.G., McManus W.F., Mason A.D., Pruitt B.A. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995, 180:273-278.
26. Herndon D.N. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995, 180:340-342.
27. Sheridan R.L., Weber J.M., Schulz J.T., Ryan C.M., Low H.M., Tompkins R.G. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999, 20:497-500.
28. van der Meer J.B., Schuttelaar M.L., Toth G.G., et al. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol 2001, 26:654-656.
29. Kardaun S.H. Toxic epidermal necrolysis/Stevens Johnson syndrome: positive outcome after treatment with dexamethasone pulse therapy. J Invest Dermatol 2004, 123. [abstract].
30. Kardaun S.H., Jonkman M.F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007, 87:144-148.
31. Schneck J., Fagot J.P., Sekula P., Sassolas B., Roujeau J.C., Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008, 58:33-40.
32. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285.
33. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
34. Mittmann N., Chan B., Knowles S., Cosentino L., Shear N. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006, 7:359-368.
35. Stella M., Clemente A., Bollero D., Risso D., Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007, 33:452-459.